Customer Letters

Please note, the following Customer Letters, in electronic format, do not replace the print version that you receive from your local Canadian Blood Services site. The print version must be retained as your file copy.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, please contact the Canadian Blood Services staff member identified within the letters or contact your local Hospital Liaison Specialist to determine if the letter is still current.

---

2012 | 2011 | 2010 |2009 | 2008 |2007 |2006 | 2005 | 2004 | 2003

Contact Lists Referenced in Customer Letters	Effective Date
Medical Directors	2008-02-01
Hospital Liaisons	2008-02-01

Letter #	Date	Title
2012-19	2012-05-16	Circular of Information – Quality Control (QC) Criteria for Red Blood Cells LR SAGM added
2012-18	2012-05-14	Corporate Name Change for Wyeth & Extended Temperature Storage for BeneFIX® Coagulation Factor IX (Recombinant) SJ Canadian Blood Services Letter BenXYN Introducing the convenience of extended room temperature storage for BeneFIX
2012-17	2012-05-01	Important Information Regarding the Introduction of Octaplasma™ (Solvent Detergent (S/D)Treated Human Plasma) Important treatment advance in Transfusion Medicine – Octaplasma® is now available in Canada Attachment #1 - Solvent Detergent Plasma Request Form Attachment #2 - Hospital Solvent Detergent Plasma Disposition Report Attachment #3 - Octaplasma Labeling First 6 Lots Attachment #4 - Octaplasma Labeling Future Labels
2012-16	2012-05-01	Change to the Shell of the Canadian Blood Services Shipping Containers
2012-15	2012-04-30	Revised dates for moves of Hamilton and London sites to Brampton
2012-14	2012-04-18	Update to the Phenotype Labelling Bug on the Red Blood Cell Component
2012-13	2012-04-12	Recommendations for the Notification of Recipients of a Blood Component Recall
2012-12	2012-04-03	Important Information Regarding Availability of Immune Globulin Products for 2012-2013
2012-11	2012-03-12	Canadian Blood Services’ Hamilton Site Move to Brampton Facility
2012-10	2012-03-08	Changes to Plasma Protein Products Distributed by Canadian Blood Services COAGULATION FACTOR Comparison Table Important treatment advance in von Willebrand disease (VWD) care - wilate® is now approved in Canada for VWD patients. New Enhanced Reconstitution device for GAMMAGARD S/D wilate®, now available in convenient 500 IU and 1000 IU vials of both FVIII and VWF per vial ADVATE 2mL SWFI for 250IU and 500IU approved for distribution in Canada
2012-09	2012-03-07	IMPORTANT INFORMATION REGARDING PATIENT IgA/Anti-IgA TESTING REQUESTS PATIENT REQUEST FOR IgA/ANTI-IgA TESTING FORM
2012-08	2012-02-29	Recommendations for Use of Prothrombin Complex Concentrates
2012-07	2012-02-27	2011 Hospital Satisfaction Survey Summary
2012-06	2012-02-21	Expanded Use of the Consignee (Customer) Notification Form
2012-02 Correction	2012-01-30	CORRECTION INFORMATION ONLY Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human)
2012-05	2012-01-26	Shipping Containers Utilized for RBC Shipments
2012-04	2012-01-25	Corporate Name Change for Talecris Biotherpeutics, Ltd & Redesigned Latex-free Stopper Grifols product stopper redesign to address complaints related to latex-free stoppers used in 100, 50 and 25 mL formats Canadian Blood Services Name Change Letter
2012-03	2012-01-23	Change in Distribution of Starches Part II
2012-02	2012-01-19	Launch of Hizentra™ 20%, Subcutaneous Immune Globulin (Human) Hizentra, 20%, Subcutaneous Immune Globulin (human), 20% solution for injection
2012-01	2012-01-09	Research Use of Blood Components

/\ Top